Lyell Immunopharma, Inc Share Price Today: Live Updates & Key Insights
Lyell Immunopharma, Inc share price today is $19.025, up -7.94%. The stock opened at $21.1 against the previous close of $20.77, with an intraday high of $21.1 and low of $19.11.
Lyell Immunopharma, Inc Share Price Chart
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc Share Price Performance
Lyell Immunopharma, Inc Institutional Holdings
Lyell Immunopharma, Inc Market Status
Lyell Immunopharma, Inc Fundamentals
Market Cap 445.63 M
PB Ratio 1.7865
PE Ratio 0.0
Enterprise Value 247.19 M
Total Assets 340.05 M
Volume 108913
Lyell Immunopharma, Inc Company Financials
About Lyell Immunopharma, Inc & investment objective
Company Information Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Organisation Biotechnology
Employees 300
Industry Biotechnology
CEO Dr. Lynn Seely M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Lyell Immunopharma, Inc FAQs
What is the share price of Lyell Immunopharma, Inc today?
The current share price of Lyell Immunopharma, Inc is $19.025.
Can I buy Lyell Immunopharma, Inc shares in India?
Yes, Indian investors can buy Lyell Immunopharma, Inc shares by opening an international trading and demat account with Motilal Oswal.
How to buy Lyell Immunopharma, Inc shares in India?
You can easily invest in Lyell Immunopharma, Inc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Lyell Immunopharma, Inc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Lyell Immunopharma, Inc.
Can I buy fractional shares of Lyell Immunopharma, Inc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Lyell Immunopharma, Inc?
Lyell Immunopharma, Inc has a market cap of $445.63 M.
In which sector does Lyell Immunopharma, Inc belong?
Lyell Immunopharma, Inc operates in the Biotechnology sector.
What documents are required to invest in Lyell Immunopharma, Inc stocks?
To invest, you typically need:
What is the PE and PB ratio of Lyell Immunopharma, Inc?
The PE ratio of Lyell Immunopharma, Inc is N/A and the PB ratio is 1.79.